drugset / Trial / NCT02738333
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objectives of this study are to evaluate the antiviral efficacy of therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) and to evaluate the safety and tolerability of LDV/SOF FDC and sofosbuvir (SOF) + ribavirin (RBV) in participants with chronic genotype 2 hepatitis C virus (HCV) infection.
Timeline
- Start
- 2016-04-12
- Primary completion
- 2017-02-14
- Completion
- 2017-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LDV/SOF | Unknown | 90 mg | Oral |
| Subject | LDV/SOF | Unknown | 400 mg | Oral |
| Subject | Ribavirin | Small molecule | 600 mg | Oral |
| Subject | Ribavirin | Small molecule | 800 mg | Oral |
| Subject | Ribavirin | Small molecule | 1000 mg | Oral |
| Subject | Sofosbuvir | Small molecule | 400 mg | Oral |